Cited 51 times in
Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 백순명 | - |
dc.date.accessioned | 2014-12-18T09:53:52Z | - |
dc.date.available | 2014-12-18T09:53:52Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0027-8874 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89034 | - |
dc.description.abstract | National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method. All statistical tests were two-sided and considered statistically significant at the .05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] = 0.52; 95% confidence interval [CI] = 0.29 to 0.94; P = .02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR = 1.03; 95% CI = 0.84 to 1.27; p = .78; P(interaction)= .04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angiogenesis Inhibitors/administration & dosage | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Colonic Neoplasms/drug therapy* | - |
dc.subject.MESH | Colonic Neoplasms/genetics* | - |
dc.subject.MESH | Colonic Neoplasms/pathology | - |
dc.subject.MESH | DNA Mismatch Repair/drug effects* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Odds Ratio | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Proto-Oncogene Proteins B-raf/genetics | - |
dc.subject.MESH | Treatment Failure | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.title | Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Life Science (의생명과학부) | - |
dc.contributor.googleauthor | Kay Pogue-Geile | - |
dc.contributor.googleauthor | Greg Yothers | - |
dc.contributor.googleauthor | Yusuke Taniyama | - |
dc.contributor.googleauthor | Noriko Tanaka | - |
dc.contributor.googleauthor | Patrick Gavin | - |
dc.contributor.googleauthor | Linda Colangelo | - |
dc.contributor.googleauthor | Nicole Blackmon | - |
dc.contributor.googleauthor | Corey Lipchik | - |
dc.contributor.googleauthor | Seong Rim Kim | - |
dc.contributor.googleauthor | Saima Sharif | - |
dc.contributor.googleauthor | Carmen Allegra | - |
dc.contributor.googleauthor | Nicholas Petrelli | - |
dc.contributor.googleauthor | Michael J. O’Connell | - |
dc.contributor.googleauthor | Norman Wolmark | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.identifier.doi | 10.1093/jnci/djt140 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01823 | - |
dc.relation.journalcode | J01896 | - |
dc.identifier.eissn | 1460-2105 | - |
dc.identifier.pmid | 23821759 | - |
dc.identifier.url | http://jnci.oxfordjournals.org/content/105/13/989.long | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Angiogenesis Inhibitors/administration & dosage | - |
dc.subject.keyword | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.keyword | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.keyword | Antibodies, Monoclonal, Humanized/therapeutic use* | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | Chemotherapy, Adjuvant | - |
dc.subject.keyword | Colonic Neoplasms/drug therapy* | - |
dc.subject.keyword | Colonic Neoplasms/genetics* | - |
dc.subject.keyword | Colonic Neoplasms/pathology | - |
dc.subject.keyword | DNA Mismatch Repair/drug effects* | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Immunohistochemistry | - |
dc.subject.keyword | Kaplan-Meier Estimate | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Neoplasm Staging | - |
dc.subject.keyword | Odds Ratio | - |
dc.subject.keyword | Organoplatinum Compounds/administration & dosage | - |
dc.subject.keyword | Proto-Oncogene Proteins B-raf/genetics | - |
dc.subject.keyword | Treatment Failure | - |
dc.subject.keyword | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | Paik, Soon Myung | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 105 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 989 | - |
dc.citation.endPage | 992 | - |
dc.identifier.bibliographicCitation | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol.105(13) : 989-992, 2013 | - |
dc.identifier.rimsid | 33755 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.